Navigation Links
Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
Date:2/17/2009

Studies presented at the 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Demonstrated Favorable Pharmacokinetics and Significant Reduction in Viral Load

TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced results from international Phase I and II clinical trials evaluating a controlled release version of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) infection. In the phase II study in treatment-naive patients infected with HCV genotype 4, 82% (n=17) and 100% (n=16) of patients receiving low and high doses of controlled release nitazoxanide, respectively, experienced undetectable serum HCV RNA (<12 IU/mL) after 12 weeks of combination therapy with peginterferon and ribavirin.

The data, part of Romark's OPTIMA HCN (OPTImizing MAnagement of Hepatitis C with Nitazoxanide) development program, were presented this weekend in an oral presentation at the 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Hong Kong. The presentation titled "Controlled Release Tablet Improves Pharmacokinetics, Viral Kinetics and Tolerability of Nitazoxanide for Treatment of Chronic Hepatitis C," abstract FP052, was given by Emmet B. Keeffe, M.D. of the Romark Institute for Medical Research, Tampa, FL.

"We continue to be encouraged by the results of the ongoing nitazoxanide clinical development program," said Jean-Francois Rossignol, M.D., Director of the Romark Institute for Medical Research and discoverer of nitazoxanide. "These data show that controlled release nitazoxanide exhibits favorable pharmacokinetics and tolerability, and - in combination with the standard of care therapy - robust antiviral activity in a small number of patients with HCV genotype 4. We look forward to reporting interim data from our U.S. studies evalua
'/>"/>

SOURCE Romark Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
2. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
3. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim
6. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
7. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
8. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
9. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
10. Savient Announces Appointment of David Gionco as Chief Financial Officer
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... Mass. , Oct. 19, 2014 NextCODE Health, ... the whole genome in real time, today announced the launch ... NextCODE Exchange , at the American Society of Human ... . To learn more, sign up and apply for free ... its unique features and benefits can be viewed here ...
(Date:10/19/2014)... October 19, 2014 The report "Chocolate, ... Share, Trade, Prices, Geography Trend and Forecast (2011 - ... category, and geography and studies the major market drivers, ... America, Europe, and Asia. , The global chocolate market ... $98.3 billion in 2016 at an estimated CAGR of ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... and Mayo Foundation,for Medical Education and Research announced ... systems biology (CSB(TM)) profiling to,breast cancer patient stratification. ... profile test to improve diagnosis and treatment for ... an exciting research and development,program with Mayo, a ...
... E. Nedwin, Ph.D., MBA to Join Genencor,s Senior ... Genencor, a division of Danisco,A/S, today announced that ... as,Executive Vice President - Technical Enzymes, effective Oct. ... Management Team, Dr. Nedwin will head the,division,s activities ...
... MUNICH, Germany, October 1 - New Product ... - Approval Requested in 28 European Countries DAIICHI ... for,approval of a new antihypertensive medication. It is a ... (ARB),Olmesartan and the calcium antagonist Amlodipin. When approved, ...
Cached Biology Technology:Genencor Appoints New Executive Vice President - Technical Enzymes 2DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin 2
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Feb. 29 /Xinhua-PRNewswire/ -- Futronic Technology Company,Limited, ... hardware products,today announced that the latest version ... and Windows 2008 Server., FinLogon is ... using proprietary fingerprint recognition technology. By a,finger ...
... of impact strata on Mars, Holden Crater; Eocene-Oligocene ... that liquid water is not responsible for recent ... Cretaceous early Albian greenhouse conditions and implications for ... Earth,s copper supply; discovery of large nitrate pools ...
... biochemistry, has received the National Science Foundation,s prestigious ... competitive funding award, designed to support the integrated ... their careers, is bestowed on those scientists and ... leaders of the 21st century. Fewer than 20 ...
Cached Biology News:Futronic Announces Microsoft Vista and Windows 2008 Server Support for Its Fingerprint Logon Software 2March GEOLOGY and GSA TODAY media highlights 2March GEOLOGY and GSA TODAY media highlights 3March GEOLOGY and GSA TODAY media highlights 4March GEOLOGY and GSA TODAY media highlights 5March GEOLOGY and GSA TODAY media highlights 6March GEOLOGY and GSA TODAY media highlights 7March GEOLOGY and GSA TODAY media highlights 8March GEOLOGY and GSA TODAY media highlights 9March GEOLOGY and GSA TODAY media highlights 10March GEOLOGY and GSA TODAY media highlights 11March GEOLOGY and GSA TODAY media highlights 12March GEOLOGY and GSA TODAY media highlights 13March GEOLOGY and GSA TODAY media highlights 14March GEOLOGY and GSA TODAY media highlights 15UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 2UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 3
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: